Lessons from the cat: Development of vaccines against lentiviruses

Veterinary Immunology and Immunopathology

Volumn 112, Issue 1-2, 2006, Pages 67-77

  Dunham, Stephen P ^a  

^a Faculty of Veterinary Medicine   (United Kingdom)

Author keywords

Cat; Feline immunodeficiency virus; Vaccine

Indexed keywords

DNA VACCINE; VIRUS VACCINE;

ARTICLE; CAT; CAT DISEASE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FELINE IMMUNODEFICIENCY VIRUS; MORBIDITY; MORTALITY; NONHUMAN;

AIDS VACCINES; ANIMALS; CAT DISEASES; CATS; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; HUMANS; IMMUNODEFICIENCY VIRUS, FELINE; LENTIVIRUS INFECTIONS; LENTIVIRUSES, FELINE; VACCINATION; VACCINES, DNA; VACCINES, INACTIVATED; VARIATION (GENETICS); VIRAL VACCINES;

BACTERIA (MICROORGANISMS); FELINE IMMUNODEFICIENCY VIRUS; FELIS CATUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 33744543714     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetimm.2006.03.013     Document Type: Article

References (70)

1. Addie D.D., Dennis J.M., Toth S., Callanan J.J., Reid S., and Jarrett O. Long-term impact on a closed household of pet cats of natural infection with feline coronavirus, feline leukaemia virus and feline immunodeficiency virus. Vet. Rec. 146 (2000) 419-424
2. Amara R.R., Patel K., Niedziela G., Nigam P., Sharma S., Staprans S.I., Montefiori D.C., Chenareddi L., Herndon J.G., Robinson H.L., McClure H.M., and Novembre F.J. A combination DNA and attenuated simian immunodeficiency virus vaccine strategy provides enhanced protection from simian/human immunodeficiency virus-induced disease. J. Virol. 79 (2005) 15356-15367
3. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., Montefiori D.C., Xu Y., Herndon J.G., Wyatt L.S., Candido M.A., Kozyr N.L., Earl P.L., Smith J.M., Ma H.L., Grimm B.D., Hulsey M.L., Miller J., McClure H.M., McNicholl J.M., Moss B., and Robinson H.L. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292 (2001) 69-74
4. Beatty J.A., Willett B.J., Gault E.A., and Jarrett O. A longitudinal study of feline immunodeficiency virus-specific cytotoxic T lymphocytes in experimentally infected cats, using antigen-specific induction. J. Virol. 70 (1996) 6199-6206
5. Bishop S.A., Stokes C.R., Gruffydd-Jones T.J., Whiting C.V., and Harbour D.A. Vaginal and rectal infection of cats with feline immunodeficiency virus. Vet. Microbiol. 51 (1996) 217-227
6. Boretti F.S., Leutenegger C.M., Mislin C., Hofmann-Lehmann R., Konig S., Schroff M., Junghans C., Fehr D., Huettner S.W., Habel A., Flynn J.N., Aubert A., Pedersen N.C., Wittig B., and Lutz H. Protection against FIV challenge infection by genetic vaccination using minimalistic DNA constructs for FIV env gene and feline IL-12 expression. AIDS 14 (2000) 1749-1757
7. Broche-Pierre S., Richardson J., Moraillon A., and Sonigo P. Evaluation of live feline immunodeficiency virus vaccines with modified antigenic properties. J. Gen. Virol. 86 (2005) 2495-2506
8. Burkhard M.J., and Dean G.A. Transmission and immunopathogenesis of FIV in cats as a model for HIV. Curr. HIV Res. 1 (2003) 15-29
9. Burkhard M.J., Valenski L., Leavell S., Dean G.A., and Tompkins W.A. Evaluation of FIV protein-expressing VEE-replicon vaccine vectors in cats. Vaccine 21 (2002) 258-268
10. Callanan J.J., Hosie M.J., and Jarrett O. Transmission of feline immunodeficiency virus from mother to kitten. Vet. Rec. 128 (1991) 332-333
11. Callanan J.J., Thompson H., Toth S.R., O'Neil B., Lawrence C.E., Willett B., and Jarrett O. Clinical and pathological findings in feline immunodeficiency virus experimental infection. Vet. Immunol. Immunopathol. 35 (1992) 3-13
12. Carpenter M.A., Brown E.W., MacDonald D.W., and O'Brien S.J. Phylogeographic patterns of feline immunodeficiency virus genetic diversity in the domestic cat. Virology 251 (1998) 234-243
13. Chan W.L., Rodgers A., Hancock R.D., Taffs F., Kitchin P., Farrar G., and Liew F.Y. Protection in simian immunodeficiency virus-vaccinated monkeys correlates with anti-HLA class I antibody response. J. Exp. Med. 176 (1992) 1203-1207
14. Chen R., Le Rouzic E., Kearney J.A., Mansky L.M., and Benichou S. Vpr-mediated incorporation of UNG2 into HIV-1 particles is required to modulate the virus mutation rate and for replication in macrophages. J. Biol. Chem. 279 (2004) 28419-28425
15. Cohen J. Is an effective HIV vaccine feasible?. Science 309 (2005) 99
16. Coleman J.K., Pu R., Martin M., Sato E., and Yamamoto J.K. HIV-1 p24 vaccine protects cats against feline immunodeficiency virus infection. AIDS 19 (2005) 1457-1466
17. Crawford P.C., Slater M.R., and Levy J.K. Accuracy of polymerase chain reaction assays for diagnosis of feline immunodeficiency virus infection in cats. J. Am. Vet. Med. Assoc. 226 (2005) 1503-1507
18. + T-cells. Nature 417 (2002) 95-98
19. Dunham S.P., Bruce J., MacKay S., Golder M.C., Jarrett O., and Neil J. Efficacy of feline immunodeficiency virus vaccines Fel-O-Vax and FIVGL8ΔIN DNA vaccine: effect of route of challange on outcome. Proceedings of the Seventh International Feline Retrovirus Research Symposium. Pisa, Italy (2004) 39
20. Dunham S.P., Flynn J.N., Rigby M.A., Macdonald J., Bruce J., Cannon C., Golder M.C., Hanlon L., Harbour D.A., Mackay N.A., Spibey N., Jarrett O., and Neil J.C. Protection against feline immunodeficiency virus using replication defective proviral DNA vaccines with feline interleukin-12 and -18. Vaccine 20 (2002) 1483-1496
21. Dunham, S.P., Jarrett, O., 2006. FIV as a model for AIDS vaccine studies. In: Friedman, H., Specter, S., Bendinelli, M. (Eds.), In vivo Models of HIV Disease and Control. Springer, New York.
22. Elder J.H., and Phillips T.R. Molecular properties of feline immunodeficiency virus (FIV). Infect. Agents Dis. 2 (1993) 361-374
23. Ferrantelli F., Kitabwalla M., Rasmussen R.A., Cao C., Chou T.C., Katinger H., Stiegler G., Cavacini L.A., Bai Y., Cotropia J., Ugen K.E., and Ruprecht R.M. Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies-implications for acquired immunodeficiency syndrome vaccine. J. Infect. Dis. 189 (2004) 71-74
24. Fevereiro M., Roneker C., Laufs A., Tavares L., and de Noronha F. Characterization of two monoclonal antibodies against feline immunodeficiency virus gag gene products and their application in an assay to evaluate neutralizing antibody activity. J. Gen. Virol. 72 (1991) 617-622
25. + T lymphocytes. Immunology 96 (1999) 220-229
26. Gebhard D.H., Dow J.L., Childers T.A., Alvelo J.I., Tompkins M.B., and Tompkins W.A. Progressive expansion of an L-selectin-negative CD8 cell with anti- feline immunodeficiency virus (FIV) suppressor function in the circulation of FIV-infected cats. J. Infect. Dis. 180 (1999) 1503-1513
27. Gemeniano M.C., Sawai E.T., and Sparger E.E. Feline immunodeficiency virus Orf-A localizes to the nucleus and induces cell cycle arrest. Virology 325 (2004) 167-174
28. Giannecchini S., Isola P., Sichi O., Matteucci D., Pistello M., Zaccaro L., Del Mauro D., and Bendinelli M. AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblasts. J. Virol. 76 (2002) 6882-6892
29. Hosie M.J., Dunsford T., Klein D., Willett B.J., Cannon C., Osborne R., Macdonald J., Spibey N., Mackay N., Jarrett O., and Neil J.C. Vaccination with inactivated virus but not viral DNA reduces virus load following challenge with a heterologous and virulent isolate of feline immunodeficiency virus. J. Virol. 74 (2000) 9403-9411
30. Hosie M.J., and Flynn J.N. Feline immunodeficiency virus vaccination: characterization of the immune correlates of protection. J. Virol. 70 (1996) 7561-7568
31. Hosie M.J., Flynn J.N., Rigby M.A., Cannon C., Dunsford T., Mackay N.A., Argyle D., Willett B.J., Miyazawa T., Onions D.E., Jarrett O., and Neil J.C. DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies. J. Virol. 72 (1998) 7310-7319
32. Hosie M.J., Klein D., Binley J.M., Dunsford T.H., Jarrett O., Neil J.C., Knapp E., Giannecchini S., Matteucci D., Bendinelli M., Hoxie J.A., and Willett B.J. Vaccination with an inactivated virulent feline immunodeficiency virus engineered to express high levels of Env. J. Virol. 79 (2005) 1954-1957
33. Hosie M.J., Osborne R., Reid G., Neil J.C., and Jarrett O. Enhancement after feline immunodeficiency virus vaccination. Vet. Immunol. Immunopathol. 35 (1992) 191-197
34. Inoshima Y., Miyazawa T., and Mikami T. In vivo functions of the auxiliary genes and regulatory elements of feline immunodeficiency virus. Vet. Microbiol. 60 (1998) 141-153
35. Ishida T., Washizu T., Toriyabe K., Motoyoshi S., Tomoda I., and Pedersen N.C. Feline immunodeficiency virus infection in cats of Japan. J. Am. Vet. Med. Assoc. 194 (1989) 221-225
36. Karlas J.A., Siebelink K.H., Peer M.A., Huisman W., Cuisinier A.M., Rimmelzwaan G.F., and Osterhaus A.D. Vaccination with experimental feline immunodeficiency virus vaccines, based on autologous infected cells, elicits enhancement of homologous challenge infection. J. Gen. Virol. 80 (1999) 761-765
37. + lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J. Immunol. 164 (2000) 1602-1611
38. Kusuhara H., Hohdatsu T., Okumura M., Sato K., Suzuki Y., Motokawa K., Gemma T., Watanabe R., Huang C., Arai S., and Koyama H. Dual-subtype vaccine (Fel-O-Vax FIV) protects cats against contact challenge with heterologous subtype B FIV infected cats. Vet. Microbiol. 108 (2005) 155-165
39. Lerner D.L., Wagaman P.C., Phillips T.R., Prospero-Garcia O., Henriksen S.J., Fox H.S., Bloom F.E., and Elder J.H. Increased mutation frequency of feline immunodeficiency virus lacking functional deoxyuridine-triphosphatase. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 7480-7484
40. Levy J.K., Crawford P.C., and Slater M.R. Effect of vaccination against feline immunodeficiency virus on results of serologic testing in cats. J. Am. Vet. Med. Assoc. 225 (2004) 1558-1561
41. Lockridge K.M., Chien M., Dean G.A., Stefano C.K., Montelaro R.C., Luciw P.A., and Sparger E.E. Protective immunity against feline immunodeficiency virus induced by inoculation with vif-deleted proviral DNA. Virology 273 (2000) 67-79
42. Matteucci D., Pistello M., Mazzetti P., Giannecchini S., Isola P., Merico A., Zaccaro L., Rizzuti A., and Bendinelli M. AIDS vaccination studies using feline immunodeficiency virus as a model: immunisation with inactivated whole virus suppresses viraemia levels following intravaginal challenge with infected cells but not following intravenous challenge with cell-free virus. Vaccine 18 (1999) 119-130
43. Matteucci D., Poli A., Mazzetti P., Sozzi S., Bonci F., Isola P., Zaccaro L., Giannecchini S., Calandrella M., Pistello M., Specter S., and Bendinelli M. Immunogenicity of an anti-clade B feline immunodeficiency fixed-cell virus vaccine in field cats. J. Virol. 74 (2000) 10911-10919
44. Miyazawa T., Tomonaga K., Kawaguchi Y., and Mikami T. The genome of feline immunodeficiency virus. Arch. Virol. 134 (1994) 221-234
45. Moench T.R., Whaley K.J., Mandrell T.D., Bishop B.D., Witt C.J., and Cone R.A. The cat/feline immunodeficiency virus model for transmucosal transmission of AIDS: nonoxynol-9 contraceptive jelly blocks transmission by an infected cell inoculum. AIDS 7 (1993) 797-802
46. Natoli E., Say L., Cafazzo S., Bonanni R., Schmid M., and Pontier D. Bold attitude makes male urban feral domestic cats more vulnerable to feline immunodeficiency virus. Neurosci. Biobehav. Rev. 29 (2005) 151-157
47. O'Neil L.L., Burkhard M.J., and Hoover E.A. Frequent perinatal transmission of feline immunodeficiency virus by chronically infected cats. J. Virol. 70 (1996) 2894-2901
48. Paroli M., Propato A., Accapezzato D., Francavilla V., Schiaffella E., and Barnaba V. The immunology of HIV-infected long-term non-progressors-a current view. Immunol. Lett. 79 (2001) 127-129
49. Patterson L.J., Malkevitch N., Venzon D., Pinczewski J., Gomez-Roman V.R., Wang L., Kalyanaraman V.S., Markham P.D., Robey F.A., and Robert-Guroff M. Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J. Virol. 78 (2004) 2212-2221
50. Pedersen N.C., Ho E., Brown M.L., and Yamamoto J.K. Isolation of a T lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 235 (1987) 790-793
51. Pu R., Coleman J., Coisman J., Sato E., Tanabe T., Arai M., and Yamamoto J.K. Dual-subtype FIV vaccine (Fel-O-Vax FIV) protection against a heterologous subtype B FIV isolate. J. Feline Med. Surg. 7 (2005) 65-70
52. Pu R., Coleman J., Omori M., Arai M., Hohdatsu T., Huang C., Tanabe T., and Yamamoto J.K. Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates. AIDS 15 (2001) 1225-1237
53. Richardson J., Broche S., Baud S., Leste-Lasserre T., Femenia F., Levy D., Moraillon A., Pancino G., and Sonigo P. Lymphoid activation: a confounding factor in AIDS vaccine development?. J. Gen. Virol. 83 (2002) 2515-2521
54. Richardson J., Moraillon A., Baud S., Cuisinier A.M., Sonigo P., and Pancino G. Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope. J. Virol. 71 (1997) 9640-9649
55. Rowland-Jones S., Sutton J., Ariyoshi K., Dong T., Gotch F., McAdam S., Whitby D., Sabally S., Gallimore A., and Corrah T. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat. Med. 1 (1995) 59-64
56. Sankaran S., Guadalupe M., Reay E., George M.D., Flamm J., Prindiville T., and Dandekar S. Gut mucosal T-cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected non-progressors. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 9860-9865
57. Shimojima M., Miyazawa T., Ikeda Y., McMonagle E.L., Haining H., Akashi H., Takeuchi Y., Hosie M.J., and Willett B.J. Use of CD134 as a primary receptor by the feline immunodeficiency virus. Science 303 (2004) 1192-1195
58. Siebelink K.H., Tijhaar E., Huisman R.C., Huisman W., de Ronde A., Darby I.H., Francis M.J., Rimmelzwaan G.F., and Osterhaus A.D. Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines. J. Virol. 69 (1995) 3704-3711
59. Slobod K.S., Coleclough C., Brown S.A., Stambas J., Zhan X., Surman S., Jones B.G., Zirkel A., Freiden P.J., Brown B., Sealy R., Bonsignori M., and Hurwitz J.L. Clade, Country and Region-specific HIV-1 Vaccines: Are they necessary?. AIDS Res. Ther. 2 (2005) 3
60. Sodora D.L., Shpaer E.G., Kitchell B.E., Dow S.W., Hoover E.A., and Mullins J.I. Identification of three feline immunodeficiency virus (FIV) env gene subtypes and comparison of the FIV and human immunodeficiency virus type 1 evolutionary patterns. J. Virol. 68 (1994) 2230-2238
61. Staprans S.I., Barry A.P., Silvestri G., Safrit J.T., Kozyr N., Sumpter B., Nguyen H., McClure H., Montefiori D., Cohen J.I., and Feinberg M.B. Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T-cell response to the SIV envelope protein. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 13026-13031
62. Steinrigl A., and Klein D. Phylogenetic analysis of feline immunodeficiency virus in Central Europe: a prerequisite for vaccination and molecular diagnostics. J. Gen. Virol. 84 (2003) 1301-1307
63. Stevens R., Howard K.E., Nordone S., Burkhard M., and Dean G.A. Oral immunization with recombinant listeria monocytogenes controls virus load after vaginal challenge with feline immunodeficiency virus. J. Virol. 78 (2004) 8210-8218
64. Stott E.J. Anti-cell antibody in macaques. Nature 353 (1991) 393
65. Uhl E.W., Heaton-Jones T.G., Pu R., and Yamamoto J.K. FIV vaccine development and its importance to veterinary and human medicine: a review FIV vaccine 2002 update and review. Vet. Immunol. Immunopathol. 90 (2002) 113-132
66. Wang B., Boyer J., Srikantan V., Coney L., Carrano R., Phan C., Merva M., Dang K., Agadjanan M., Gilbert L., Ugen K.E., Williams W.V., and Weiner D.B. DNA inoculation induces neutralizing immune responses against human immunodeficiency virus type 1 in mice and non-human primates. DNA Cell Biol. 12 (1993) 799-805
67. Willett B.J., Flynn J.N., and Hosie M.J. FIV infection of the domestic cat: An animal model for AIDS. Immunol. Today 18 (1997) 182-189
68. Willett B.J., Hosie M.J., Neil J.C., Turner J.D., and Hoxie J.A. Common mechanism of infection by lentiviruses. Nature 385 (1997) 587
69. Yamamoto J.K., Hohdatsu T., Olmsted R.A., Pu R., Louie H., Zochlinski H.A., Acevedo V., Johnson H.M., Soulds G.A., and Gardner M.B. Experimental vaccine protection against homologous and heterologous strains of feline immunodeficiency virus. J. Virol. 67 (1993) 601-605
70. Yamamoto J.K., Okuda T., Ackley C.D., Louie H., Pembroke E., Zochlinski H., Munn R.J., and Gardner M.B. Experimental vaccine protection against feline immunodeficiency virus. AIDS Res. Hum. Retroviruses 7 (1991) 911-922